Skip to main content

Advertisement

Table 2 Summary of adverse events

From: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Toxicity Peptide Total patients (n = 11)
0.5 mg (n = 3) 1.0 mg (n = 3) 3.0 mg (n = 5)
Grade* Grade Grade Grade (%)
1 2 3 1 2 3 1 2 3 1 2 3
Dermatology/skin             
  Reaction at the injection site 2 0 0 3 0 0 4 0 0 9 (81.8) 0 (0.0) 0 (0.0)
Hematological             
  Leukocyte 0 0 2 0 0 2 0 1 2 0 (0.0) 1 (9.1) 6 (54.5)
  Neutrocyte 0 1 1 0 1 1 0 2 1 0 (0.0) 4 (36.4) 3 (27.3)
  Hemoglobin 1 1 1 1 1 1 1 1 1 3 (27.3) 3 (27.3) 3 (27.3)
  Platelet 1 0 0 0 0 1 3 0 0 4 (36.4) 0 (0.0) 1 (9.1)
Non-hematological             
  Esophagitis 0 1 0 2 0 0 2 1 0 4 (36.4) 2 (18.2) 0 (0.0)
  AST 1 0 0 1 0 0 0 0 0 2 (18.2) 0 (0.0) 0 (0.0)
  ALT 0 0 0 0 0 0 1 0 0 1 (9.1) 0 (0.0) 0 (0.0)
  Creatinine 0 0 0 0 0 0 0 0 0 0 (0.0) 0 (0.0) 0 (0.0)
  Nausea/vomiting 1 0 0 0 1 0 0 0 0 1 (9.1) 2 (18.2) 0 (0.0)
  Diarrhea 0 1 0 0 0 0 0 0 0 0 (0.0) 1 (9.1) 0 (0.0)
Stomatitis/pharyngitis 0 1 0 0 1 0 0 1 0 0 (0.0) 3 (27.3) 0 (0.0)
  Hyponatremia 0 2 0 1 0 0 1 1 0 2 (18.2) 3 (27.3) 0 (0.0)
  1. *Adverse events were graded according to the CTCAE v3.0.